Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes

Simple item page
dc.contributor.authorSarmiento, Mauricio
dc.contributor.authorRojas, Patricio
dc.contributor.authorGutierrez, Catherine
dc.contributor.authorQuezada, Jacqueline
dc.contributor.authorJara, Veronica
dc.contributor.authorCampbell, James
dc.contributor.authorMaria, Garcia
dc.contributor.authorJose, Max
dc.contributor.authorVicenteSandoval
dc.contributor.authorVergara, Max
dc.contributor.authorTriantafilo, Nicolas
dc.contributor.authorOcqueteau, Mauricio
dc.date.accessioned2025-01-20T20:07:20Z
dc.date.available2025-01-20T20:07:20Z
dc.date.issued2023
dc.description.abstractThis retrospective study shows the feasibility of performing autologous stem cell transplantation in lymphoma using a non-cryopreserved strategy with conventional conditionings administered in fewer days. In a cohort of 61 patients, benefits of avoiding DMSO cryopreservation were observed. Background: Hematopoietic autologous stem cell transplantation (ASCT) is a validated therapeutic strategy for lymphoma treatment and precise well-tolerated conditioning. Several conditioning methods are available, but the most commonly used are CVB, BEAM, and ICE, which are conventionally administered in 6 to 7 days. Since 2015, our program has moved toward noncr yopreser ved platforms that require concise times; therefore, we have modified the conditioning by reducing it to 4 to 5 days. In this study, we show our experience. Methods: We compared ASCT performed in our program before and after 2015 in lymphoma patients. Between 2000 and 2014 and from 2015 to 2022, we performed 46 and 61 ASCT procedures, respectively. Results: Since 2015, we observed a greater number of infused stem cells, fewer episodes of febrile neutropenia (60% vs. 37% P = .008), shorter hospitalizations (30 vs. 18 days P = .001), faster engraftment (20 vs. 14 days P = .001) and better progression-free survival (72 vs. 44 months P = .002). Additionally, a prolonged overall survival was observed at these results, and this prolonged survival is difficult to interpret due to the short follow-up. Conclusion: In conclusion, conditioning adjusted for a noncryopreserved strategy offers at least similar or even better results than the cr yopreser ved strategy. Prospective studies are warranted.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.clml.2023.04.001
dc.identifier.eissn2152-2669
dc.identifier.issn2152-2650
dc.identifier.urihttps://doi.org/10.1016/j.clml.2023.04.001
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91791
dc.identifier.wosidWOS:001053835300001
dc.issue.numero7
dc.language.isoen
dc.pagina.final551
dc.pagina.inicio545
dc.revistaClinical lymphoma myeloma & leukemia
dc.rightsacceso restringido
dc.subjectDMSO
dc.subjectAutologous stem cell transplantation
dc.subjectLymphoma
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAutologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes
dc.typeartículo
dc.volumen23
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas